Cologne, Germany, February 22, 2016 - CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications. Cell Culture World Congress, February 23 – 24, Munich, Germany The Cell Culture World Congress assembles leaders from the international pharmaceutical and biotechnology industries to discuss innovative approaches and recent developments in the cell culture and biomanufacturing industry. CEVEC will be hosting its own booth #33 during the conference. In addition, Dr. Nico Scheer, Vice President Business Development Glycoproteins, will talk about “Novel Human Suspension Cell Lines for Scalable Production of Viral Vectors and Proteins previously out of Reach” on February 24 at 1 pm CET at the Sofitel Munich Bayerpost. IS Biotech 6th Annual Spring Meeting 2016, March 7 - 9, Washington, DC, USA The congress is one of the most important platforms for companies developing and producing biopharmaceuticals worldwide to discuss advanced process and analytical techniques as well as bioprocess technologies with focus on scalable and reproducible processes, as well as the assays needed to insure indisputable quality in industrial settings. It is hosted annually by the International Society for BioProcess Technology. On March 09 at 10:30am ET, Dr. Nicole Faust, CEVEC’s Chief Scientific Officer, will promote CEVEC’s CAP®GT technology in a presentation titled “CAP®GT - Novel Human Suspension Cell Lines for Scalable Production of Viral Vectors” to professionals from the pharmaceutical and biotechnology industries. SFTCG Annual Congress, March 09 - 10, Marseille, France The SFTCG Annual Congress of the French Society for Cell and Gene Therapy is an important platform for clinicians, government authorities, regulatory agencies, pharmaceutical and biotechnology companies as well as media to discuss progress in the field of biotherapy, regenerative medicine and technology based on gene transfer and cell biology, and to promote the effective transfer of research technology to the clinic. To meet the Company, please visit booth #3 at the Palais des Arts, Palais Chanot in Marseille, France. About CEVEC: CEVEC is a global solution provider for the production of biopharmaceuticals using a unique human cell-based expression system. The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems. CEVEC’s CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express glycoproteins and provide authentic human post-translational modifications. CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins. Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology form one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the GMP production in CAP®Go and CAP®GT cells.
